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ABSTRACT
Background To prevent atrial ﬁbrillation (AF) recurrence
after catheter ablation, pulmonary venous isolation (PVI)
at an antral level is more effective than segmental ostial
ablation. Cryoablation around the pulmonary venous (PV)
ostia for AF therapy is potentially safer compared to
radiofrequency ablation (RFA). The aim of this study was
to investigate the efﬁcacy of a strategy using a large
cryoablation balloon to perform antral cryoablation with
‘touch-up’ ostial cryoablation for PVI in patients with
paroxysmal and persistent AF.
Methods Paroxysmal and persistent AF patients
undergoing their ﬁrst left atrial ablation were recruited.
After cryoballoon therapy, each PV was assessed for
isolation and if necessary, treated with focal ostial
cryoablation until PVI was achieved. Follow-up with
Holter monitoring was performed. Clinical outcomes of
the cryoablation protocol were compared, with
consecutive patients undergoing PVI by RFA.
Results 124 consecutive patients underwent
cryoablation. 77% of paroxysmal and 48% of persistent
AF subjects were free from AF at 12 months after
a single procedure. Over the same time period, 53
consecutive paroxysmal AF subjects underwent PVI with
RFA and at 12 months, 72% were free from AF at
12 months (p¼NS). There were too few persistent AF
subjects (n¼8) undergoing solely PVI by RFA as
a comparison group. Procedural and ﬂuoroscopic times
during cryoablation were signiﬁcantly shorter than RFA.
Conclusions PV isolation can be achieved in less than
2 h by a simple cryoablation protocol with excellent
results after a single intervention, particularly for
paroxysmal AF.
BACKGROUND
Pulmonary venous isolation (PVI) remains the
cornerstone of most atrial ﬁbrillation (AF) ablation
procedures.Onitsown,itis successfulinpreventing
recurrence of paroxysmal AF in 60e80% of subjects
undergoing PVI after a single procedure.
1 2 In abla-
tion of persistent AF, PVI is usually the ﬁrst step in
a stepwise approach to terminate AF.
3
The shallow learning curve in performing PVI
is partly due to variable PV anatomy, which
results in difﬁculty in appreciating the complex
three-dimensional anatomy of the left atrium (LA)
and the pulmonary veins and in catheter manipu-
lation around the LA and PV ostia.
4 Pulmonary
venous isolation at the antral level is often preferred
in order to include ostial foci within the level of
isolation and minimise the risk of PV stenosis. To
this extent, antral ablation has been shown to be
more effective than ostial segmental ablation in
preventing AF recurrence.
5
With these considerations in mind, ablation
technology that could deliver circumferential antral
ablation centred on the PVostia would facilitate AF
ablation. Although a range of different ablation
energy sources (most commonly radiofrequency
energy and cryotherapy) are available, cryotherapy
offers a theoretical advantage in that it does not
disrupt target tissue architecture and could reduce
complications such as pulmonary venous stenosis
and atrio-oesphageal ﬁstulation.
6 7 To date, no case
of pulmonary venous stenosis, atrio-oesophageal
ﬁstulation or coronary occlusion has been reported
during cryoablation for AF. In this study, results are
reported of a protocol incorporating the use of
a large cryoablation balloon to perform antral
cryoablation with ‘touch-up’ focal ostial cryoa-
blation to isolate PVs in patients with paroxysmal
and persistent AF undergoing their index ablation
procedure. In addition, the medium-term results of
the large cryoablation balloon protocol were
compared with those from consecutive AF patients
undergoing PVI using conventional radiofrequency
ablation. (RFA)
METHODS
Patient selection
Patients with symptomatic, medically refractory
AF referred for ablation from May 2006 to May
2009 were recruited. Subjects had either paroxy-
smal AF (deﬁned as self-terminating AF episodes
lasting <7 days) or early persistent AF (deﬁned as
episodes of AF that lasted >7 days, requiring direct
current cardioversion to restore sinus rhythm and
transition from a clinical pattern of paroxysmal AF
in the past 12 months). All patients were under-
going their ﬁrst AF ablation procedure.
Informed consent was obtained from all patients
prior to the procedure. All antiarrhythmic agents,
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Heart rhythm disordersexcept amiodarone, were stopped at least 5 half lives before the
procedure. In patients receiving oral anticoagulants, warfarin
was stopped 5 days prior to the procedure with bridging
tinzaparin (175 IU/kg). On the day of the procedure, trans-
oesophageal echocardiography excluded intracardiac thrombus.
No preprocedural imaging was performed to assess pulmonary
venous anatomy.
Cryoablation protocol
Venous access was obtained from the right femoral vein, through
which two 8 French sheaths (SR0 sheath, St. Jude Medical,
St Paul, Minnesota, USA) were introduced into the left atrium
via two separate transeptal punctures. A curvilinear mapping
catheter (Inquiry Optima, St Jude Medical, USA or Lasso,
Biosense Webster, Diamond Bar, California, USA) was intro-
duced via one of the transeptal sheaths to map the PV ostia.
Contrast pulmonary venography was performed with a 7 French
NIH catheter for all targeted PVs and the PV mapping catheter
was positioned at every targeted PVostium to conﬁrm electrical
connection of the PVat baseline. Over an exchange length 0.035-
inch guidewire introduced into the left superior PV, an 8 Fr
transeptal sheath was exchanged for a 15 Fr deﬂectable sheath
(Flexcath, Medtronic, Minneapolis, Minnesota, USA) to allow
introduction of a 28 mm cryoablation balloon (Arctic Front,
Medtronic, USA). This was the only cryoballoon used for all
cases. The Arctic Front cryoballoon is a deﬂectable ‘balloon
within a balloon’ catheter, whereby refrigerant is delivered into
the inner balloon. A constant vacuum applied between the inner
and outer balloon prevents the leakage of refrigerant into the
circulation in the event of a defect in the inner balloon. Over
a guidewire introduced ﬂuoroscopically into each targeted PV,
the cryoballoon was inﬂated in the left atrium before it was
advanced into the PV antrum (ﬁgure 1). Any point of contact
between the endothelium and balloon was ablated. A deﬂectable
quadripolar catheter was introduced via the left femoral vein for
either differential atrial pacing or pacing in the superior vena
cava to capture the right phrenic nerve.
After the introduction of the Arctic Front catheter into
each vein sequentially over a 0.035-inch guidewire, 50% contrast
was injected distally via the central lumen to conﬁrm a good
seal between the balloon and the pulmonary venous antra.
Two 5 min cryoballoon applications were applied to each
PV, aiming for a trough temperature of less than  408C. If
a good PV seal could not be achieved, the orientation of the
Arctic Front catheter was adjusted by either deﬂecting
the catheter and/or Flexcath guidewire or by manipulating the
guidewire into a different branch of the PV. The lowest (trough)
temperature achieved during each cryoballoon application was
recorded.
During cryoballoon applications to the right-sided PVs, the
right phrenic nerve was captured by pacing (1500 ms CL, 20 mA
output) in the superior vena cava. The operator monitored the
strength of right hemidiaphragmatic contractions by palpation
in the right hypochondrium to quickly detect injury to the right
phrenic nerve. Cryoballoon applications were immediately
terminated when any attenuation of the strength of right
hemidiaphragmatic contractions was felt.
After each PV antrum was treated with two cryoballoon
applications, the PV ostia were remapped with the curvilinear
mapping catheter and any residual LAePV connections were
treated by focal cryoablation (Freezor Max, Medtronic, USA) to
achieve PV isolation. This electrophysiological end point of
entrance block was reconﬁrmed at the end of the procedure. In
persistentAFpatients,directcurrentcardioversionwasperformed
to restore sinus rhythm. If typical atrial ﬂutter had been previ-
ously documented during electrocardiographic monitoring,
cavotricuspid isthmus ablation was performed using an 8 mm
tipped radiofrequency catheter (IBI, St Jude Medical, USA) (60W,
608C) until bidirectional isthmus block was achieved.
Pulmonary venous isolation by conventional radiofrequency
ablation
Consecutive patients undergoing PVI using conventional radio-
frequency ablation at St Mary’s Hospital, London, from May
Figure 1 Positions of inﬂated 28 mm
cryoballoon at the four pulmonary
venous antra in the same paroxysmal
atrial ﬁbrillation (AF) patient. Note the
hold-up of contrast in the pulmonary
veins due to balloon occlusion of the
antra. A quadripolar catheter is
positioned in the superior vena cava to
capture the right phrenic nerve. All four
pulmonary veins (PV) were isolated
after two cryoballoon applications to
each PV.
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Heart rhythm disorders2006 to May 2009 were recruited as a comparison group. The
following groups of patients were excluded:
A. those undergoing repeat procedures for recurrent AF (n¼90);
B. those undergoing pulmonary venous isolation using other
investigational devices such as the Hansen Robotic Catheter
system (Hansen Medical, Mountain View, California, USA),
MeshAblator (Bard Inc., Lowell, Massachusetts, USA),
Ablation Frontiers (Medtronic, USA), etc. (n¼108);
C. those who received additional left atrial ablation lesions such
as ablation of complex fractionated atrial electrograms or
linear lesions (n¼87).
Circumferential antral ablation using a 4 mm cooled tipped
catheter (Thermocool, Biosense Webster, USA), limited to
25e35W and 17 ml/min ﬂow was performed around ipsilateral
pairs of pulmonary veins, guided by either ﬂuoroscopy or
a three-dimensional mapping system (Carto, Biosense Webster,
USA). Following the creation of two encircling lesion sets,
additional ostial segmental ablation guided by a curvilinear
mapping catheter was carried out until veins were isolated with
entrance block set as the same electrophysiological end point.
Similarly, if typical atrial ﬂutter had been documented during
electrocardiographic monitoring either before or during the
procedure, cavotricuspid isthmus ablation was performed using
the same catheter (35W, 17 ml/min), until bidirectional isthmus
block was achieved.
Postoperative care and follow-up
After the procedure, oral anticoagulation with warfarin was
resumed with bridging tinzaparin continued until international
normalised ratios (INRs) were therapeutic. All antiarrhythmic
agents that were discontinued prior to the procedure were
recommenced, with a view to stopping all antiarrhythmic agents
after 3 months if patients remained free from AF. A 3-month
blanking period was applied such that any AF recurrence during
this period was not considered as treatment failure. Follow-up
was performed by clinic visits at 1, 3, 6 and subsequently
6 monthly intervals with repeated 24 h Holter monitoring and
event recorders. All patients had at least 6 months follow-up.
Recurrence was deﬁned as any documented episode of AF (both
symptomatic and asymptomatic) or atrial tachycardia lasting for
more than 30 s.
Statistical analysis
Continuous data are given as mean6standard deviation. Student
t test was used to compare differences between groups. Recur-
rence-free survival over time was calculated by Kaplan-Meier
method and p<0.05 was considered signiﬁcant. All analyses
were performed using Prism 4.0. (Graphpad, USA)
RESULTS
Patient characteristics
In total, 177 patients were recruited in a 3-year period from May
2006 to May 2009. Of these, 124 patients underwent cryoa-
blation. The mean age of patients undergoing cryoablation was
58.569.8 years, with 77% being men. Nearly all subjects had
normal left ventricular function. Hypertension was the most
common comorbidity. Ten per cent of subjects had previously
undergone cavotricuspid isthmus ablation for typical atrial
ﬂutter. The persistent AF group was older and had larger left
atria compared to the paroxysmal AF group. Baseline charac-
teristics of paroxysmal and persistent AF patients undergoing
cryoablation are shown in table 1.
Over the same period, 53 subjects with paroxysmal AF
underwent PVI using RFA. Only eight persistent AF subjects
had solely PVI as their index procedure, and this small cohort
size precluded any meaningful comparison of outcomes between
RFA and cryoablation of persistent AF. There were no signiﬁcant
differences in baseline characteristics between paroxysmal AF
subjects undergoing either cryoablation or RFA (table 2).
Acute procedural results
Cryoablation
Four-hundred and ninety-two PVs were targeted. Four right
inferior pulmonary veins were too small to introduce the PV
mapping catheter to conﬁrm isolation. Mean procedural and
ﬂuoroscopic times were 110627 and 28610 min respectively.
Although 83% of pulmonary veins were isolated with cryo-
balloon applications alone, only 40% of patients had all targeted
PVs isolated with theuse ofthe cryoballoon alone with two 300 s
applications to each PV. Ostial focal cryoablation to a mean of 1.5
PV was required in the remaining 60% of patients. In all PVs
except the left upper pulmonary vein (LUPV), PV isolation was
associated with lower mean trough temperature achieved during
balloon cryotherapy (table 3). All but two persistent AF subjects
required cardioversion at the end of procedure to restore sinus
rhythm. In the two subjects, AF organised into typical atrial
ﬂutter, which terminated into sinus rhythm during cavotricuspid
isthmus ablation. After left atrial cryotherapy, 17 paroxysmal AF
Table 1 Baseline characteristics of paroxysmal and persistent atrial
ﬁbrillation (AF) subjects undergoing cryoablation
Paroxysmal
AF (n[90)
Persistent
AF (n[34) p
Age (years) 57.369.4 61.7610.4 0.01
Men (%) 75 82 NS
Mean LA diameter (mm) 39.667.1 43.167.0 0.04
LVEDD (mm) 49.566.7 50.967.4 NS
Ejection fraction (%) 65.068.8 64.0610.1 NS
Duration of AF (years) 5.664.1 5.863.3 NS
Number of failed antiarrhythmic drugs 2.160.6 2.160.6 NS
Comorbidities
< Hypertension 42 (47%) 20 (59%)
< Coronary artery disease requiring
CABG or PCI
5 (6%) 0
Prior ablations
< Cavotricuspid isthmus ablation 10 (11%) 3 (9%)
CABG, coronary artery bypass graft; LA, left atrium; LVEDD, left ventricular end diastolic
diameter; PCI, percutaneous coronary intervention.
Table 2 Comparison between paroxysmal atrial ﬁbrillation (AF)
subjects undergoing cryoablation and radiofrequency ablation
Paroxysmal AF subjects undergoing
Cryoablation
(n[90)
Conventional
Radiofrequency
Ablation (n[53) p
Age (years) 57.369.4 59.369.7 NS
Men (%) 75 77 NS
Mean LA diameter (mm) 39.667.1 41.666.5 NS
LVEDD (mm) 49.566.7 47.866.5 NS
Ejection fraction (%) 65.068.8 60.367.3 NS
Duration of AF (years) 5.664.1 6.064.8 NS
Number of failed antiarrhythmic drugs 2.160.6 1.960.6 NS
Comorbidities
< Hypertension 42 (47%) 14 (26%)
< Coronary artery disease requiring
CABG or PCI
5 (6%) 3 (6%)
Prior ablations
< Cavotricuspid isthmus ablation 10 (11%) 4 (8%)
CABG, coronary artery bypass graft; LA, left atrium; LVEDD, left ventricular end diastolic
diameter; PCI, percutaneous coronary intervention.
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Heart rhythm disorderssubjects and four persistent AF subjects had cavotricuspid
isthmus ablation.
Radiofrequency ablation
In 53 paroxysmal AF subjects, 211 PVs were targeted and 99%
(209/211) of PVs were isolated. Six patients had cavotricuspid
isthmus ablation after PVI. An electroanatomical mapping
system was used in 51 out of 53 cases. Mean procedural and
ﬂuoroscopic times were 208658 and 62636 min respectively,
which were signiﬁcantly longer than cryoablation procedures for
paroxysmal AF (p<0.001) (table 4).
Follow-up
Cryoablation
Mean follow-up was 13.367.4 months, with 644 Holter
recordings analysed. Arrhythmia-free survival curves for the
entire group, paroxysmal and persistent AF subjects are shown
in ﬁgure 2. At 12 months follow-up, 77% of the paroxysmal AF
subjects and 48% of persistent AF subjects were free from AF
recurrence after a single procedure. There was a signiﬁcant
difference in arrhythmia-free survival between the paroxysmal
and persistent AF groups (p¼0.002). Among patients free from
AF at 12 months, nine out of 69 paroxysmal AF and two out of
15 persistent AF subjects were still on antiarrhythmic medica-
tion for frequent atrial ectopy. No organised atrial tachycardias
were detected during follow-up, with AF being the only recur-
rent arrhythmia.
Radiofrequency ablation
At 12 months, 72% of paroxysmal AF subjects who underwent
RFA (ﬁve on previously ineffective antiarrhythmics, 27 off
antiarrhythmic agents) were free from AF compared to 77% of
the paroxysmal AF subjects who underwent cryoablation (nine
on previously ineffective antiarrhythmics, 60 off antiarrhyth-
mics). Survival curves are shown in ﬁgure 3, with no statistical
difference between the two curves.
Complications
Five major complications occurred (table 4). Pericardial effusions
requiring drainage occurred in two patients undergoing RFA and
one patient undergoing cryoablation, in the latter due to
a guidewire perforating the side-branch of the LUPV before any
cryoablation was delivered. Uniquely in the cryoablation group,
there were two cases of transient right phrenic nerve palsies,
which resolved within 3 and 14 months. The phrenic nerve
palsy that took 14 months to recover was caused by unmoni-
tored cryoablation of the right lower PV. As a result of this
patient, phrenic nerve monitoring was extended to include
cryotherapy of the right lower PV, whereas earlier in the series it
had only been applied to cryotherapy of the right upper PV.
Table 4 Comparison between paroxysmal atrial ﬁbrillation (AF)
subjects undergoing cryoablation and conventional radiofrequency
ablation
Paroxysmal AF
subjects undergoing
Cryoablation
(n[90)
Conventional
radiofrequency
ablation (n[53) p
Follow-up (months) 14.967.7 15.667.4 NS
Additional
cavotricuspid ablation
17 (19%) 6 (11%)
Procedural time (min) 108628 208658 <0.001
Fluoroscopic time (min) 27696 2 636 <0.001
Complications One pericardial
effusion, two transient
phrenic nerve palsies
Two pericardial
effusion unrelated to
transeptal puncture
requiring drainage
Table 3 Acute success of 28 mm cryoballoon in achieving pulmonary
venous isolation
Targeted
veins
Isolated with
cryoballoon alone
Mean trough
temperature
when isolation
achieved (8C)
Mean trough
temperature
when isolation not
achieved (8C) p
LUPV 83%  49.466.5  46.064.7 NS
LLPV 95%  45.567.5  40.764.9 <0.01
RUPV 85%  49.165.4  45.667.9 0.03
RLPV 68%  42.166.9  38.464.5 <0.01
All PV 83%  46.667.3  41.067.2 0.02
All Patients 40%
LLPV, left lower pulmonary vein; LUPV, left upper pulmonary vein; RLPV, right lower
pulmonary vein; RUPV, right upper pulmonary vein.
Figure 2 Survival curves of subjects undergoing cryoablation. PAF,
paroxysmal atrial ﬁbrillation; Per AF, persistent atrial ﬁbrillation.
Comparison between PAF and Per AF curves, p¼0.002.
Figure 3 Survival curves of paroxysmal atrial ﬁbrillation subjects
undergoing cryoablation and conventional radiofrequency ablation.
Comparison between conventional radiofrequency ablation and
cryoablation survival curves, p¼NS.
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Cryoablation
During follow-up, 17 (14%) cryoablation patients had repeat
ablation for recurrent AF. During their second procedure, 65
pulmonary veins targeted by cryoballoon ablation during the
ﬁrst procedure were re-studied. Twenty-seven per cent of PVs
remained isolated. Forty-eight PVs demonstrated electrical
reconnection (18 LUPV, 15 LLPV, ﬁve RUPV, and 10 RLPV).
Seventy-four per cent of PVs that demonstrated reconnection
were previously isolated with the cryoballoon alone, whereas
82% of PVs that maintained electrical isolation were previously
isolated with the cryoballoon alone. The mean trough temper-
ature reached during previous cryoballoon therapy to recon-
nected veins was higher compared to the temperature reached
during previous cryoballoon therapy to persistently isolated
veins (-41.965.3 C versus -45.264.6 C, p ¼0.03).
Radiofrequency ablation
During follow-up, 12 (23%) patients who underwent PVI by
RFA had a second procedure for recurrent AF. Out of 47 PVs
targeted and isolated during the ﬁrst procedure, 11 PVs (23%)
remained isolated.
All reconnected PVs were re-isolated with RFA.
DISCUSSION
The present study is the ﬁrst to show that a novel, empirical
two freeze per vein strategy utilising a large cryoballoon to
perform antral cryoablation followed by focal ostial cryoablation
to isolate selected pulmonary veins results in medium-term
outcomes comparable to RFA; with signiﬁcantly reduced
procedural and ﬂuoroscopic times.
Although the beneﬁts of cryoablation, such as minimal risks
of PV stenosis, have long been recognised, an efﬁcient delivery
platform to deliver contiguous lesions around PVostia has been
lacking until the introduction of the Arctic Front catheter
system. Pulmonary venous isolation using earlier delivery plat-
forms such as 4 mm, 6 mm tipped and expandable circular
cryoablation catheters required lengthy procedures of nearly 6 h,
and was associated with unsatisfactory clinical outcomes.
8e11
This was thought to be due to the effects of competitive
warming by blood ﬂowing past the cryocatheter reducing lesion
size. The Arctic Front catheter obstructs blood ﬂow from the PV
being treated, thereby removing this limitation.
Several centres have already reported on the feasibility of the
cryoballoon to isolate PV for treatment of paroxysmal and
persistent atrial ﬁbrillation.
12e16 In the largest series reported to
date, Neumann et al investigated the efﬁcacy of balloon cryoa-
blation in 293 paroxysmal and 53 persistent AF subjects.
15 Using
a subjective grading of 1 to 4 to assess the degree of balloon
occlusion during contrast venography, a complete occlusion was
associated with an increased probability of PVI with the cryo-
balloon alone. After a median of 12 months follow-up, 74% of
paroxysmal and 42 % of persistent AF patients were free from AF.
Van Belle et al reported a 73% freedom from recurrent AF, using
a 3-month blanking period.
17 These results are consistent with
the present ﬁndings. In addition, the present study has shown
that a lower trough temperature during cryoballoon application
is also associated with increased likelihood of acute isolation and
maintenance of long-lasting electrical disconnection when
restudied in patients undergoing repeat ablation procedures.
Some centres have used either preprocedural computer
tomography (CT), magnetic resonance imaging or periprocedural
ﬂuoroscopy to evaluate the size of the pulmonary venous ostium
before choosing to use either a smaller (23 mm) or large (28 mm)
cryoballoon.
13e15 It was believed that a closer match between the
cryoballoon size and the size of PVostium would allow for better
balloon occlusion, and in turn result in more effective lesions.
There were two potential disadvantages to this approach: ﬁrst,
the need for preprocedural CT imaging increased the cumulative
radiation dose received by the patients and overall costs, and
second, retrospective analysis suggests that the use of a smaller
cryoballoon was associated with a higher risk of right phrenic
nerve palsy through more distal right PV cryoablation.
15
In two separate small series, detailed electroanatomical mapping
was used before and after cryoballoon applications to determine
the anatomical level at which PVI isolation was achieved. When
the 23 mm balloon was used, the veins were found to be isolated
at the level of the ostium, whereas use of the 28 mm larger balloon
results in the formation of much wider, circumferential and
antrally located lesions.
18 19 In cadaveric studies, the right phrenic
nerve is not uncommonly less than 2 mm away from the anterior
aspect of the proximal segment of the right superior pulmonary
vein.
20 Therefore, it would be expected that distal ablation to
the right-sided PV (which is more likely with a 23 mm balloon)
will result in phrenic nerve injury. This complication appears to
be unique to balloon-based catheter systems delivering cryoe-
nergy, laser or focused ultrasound energy.
21
Chun et al described the feasibility of using only the larger
cryoballoon without preprocedural left atrial imaging in 27
paroxysmal AF subjects with the aim of achieving PV isolation
at the antral level and minimising the risk of phrenic nerve
palsy.
12 Although isolation was achieved in 98% of targeted
veins, three cases (11%) of transient phrenic nerve palsy still
occurred due to distal PVablations. Unlike the present protocol,
a larger number of cryoballoon applications were made partic-
ularly for the right inferior PV where a median of up to ﬁve 300 s
applications were made. In that study, phrenic nerve dysfunc-
tion was deﬁned as the loss of reliable capture from pacing in the
superior vena cava. The lower rate of phrenic nerve palsy in the
present study (1.6%), the lowest amongst all published series, is
most likely due to a combination of limiting cryoballoon
applications to two per vein, pacing the right phrenic nerve at
a higher frequency of 40 contractions/min and by palpating for
a reduction in the strength of diaphragmatic contractions in the
right hypochondria, which in the authors’ experience, precedes
the onset of complete phrenic nerve palsy. The phrenic nerve
palsy that took 14 months to recover was caused by unmoni-
tored cryoablation of the right lower PV. As a result of this
patient, phrenic nerve monitoring was extended to include
cryotherapy of the right lower PV, whereas, earlier in the series,
it had only been applied to cryotherapy of the right upper PV.
The clinical outcomes in the present study are in agreement
with previous studies for patients with paroxysmal AF and
structurally normal hearts; that PV isolation as the sole proce-
dure is effective in preventing AF recurrence in the majority of
patients. However, in subjects with persistent AF, additive
ablation strategies, combined with PVI, are required to maintain
long-term sinus rhythm. The present deﬁnition of persistent AF
was not consistent with those deﬁned in international guide-
lines, but was chosen arbitrarily with the expectation that
patients with a more recent transition from a clinical pattern of
paroxysmal AF to persistent AF would exhibit a lesser degree of
substrate remodelling and respond more favourably to PV
isolation alone. Disappointingly, the medium-term clinical
outcome for the persistent AF group was signiﬁcantly lower
than paroxysmal AF group and it is likely that additional abla-
tion lesions will be required during their index procedure to
achieve higher ﬁrst-procedural success rates.
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This report details clinical results of a novel cryoablation
protocol for AF therapy. The comparison between RFA and
cryoballoon was not randomised, although consecutive patients
undergoing PVI by different operators in the same institution in
a real-life clinical setting were recruited. The decision to apply
only two cryoballoon applications per vein was based on early
experience with the Arctic Front and ultrasound balloon cathe-
ters; and in keeping with other studies whereby a median of two
applications was required to isolate all PVs except the right
inferior PV. Only 24 h Holter monitoring was performed to
detect asymptomatic AF and more episodes may have been
detected if longer recording durations were used. Limiting the
total number of cryoballoon applications allowed for a shorter
procedural time but did increase procedural cost, as 60% of the
cryoablation cohort required a second catheter to ensure
achievement of PV isolation.
CONCLUSIONS
Pulmonary venous isolation can be achieved in less than 2 h by
a simple cryoablation protocol with excellentresultsafter asingle
intervention, particularly for paroxysmal AF. Monitoring of
phrenic nerve function by continuous pacing and palpating the
vigour of diaphragmatic contractions is essential in minimising
the risk of phrenic nerve palsy during balloon cryoablation.
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